Extended Data Fig. 6: Combination of MRD status, BRAF mutation status, and MSI status is predictive of DFS.
From: ctDNA-based molecular residual disease and survival in resectable colorectal cancer
a-b. Kaplan-Meier estimates for DFS stratified by BRAF mutation status (wild-type versus V600E) and MSI status (MSI high versus MSS) among patients who were MRD-positive (a) or MRD-negative (b). P = 4.95 × 10−7 (b, BRAF WT & MSI high). Two-sided Chi-square test for bar plots: P = 6.50 × 10−6 (b). Hazard ratios (HRs) and 95% CIs were calculated using the Cox proportional hazard model. P values were calculated using the two-sided log-rank test. This analysis was landmarked from the date of the MRD time point. Median DFS and percent DFS at 24 months are estimated from the landmark time point. Abbreviations: WT, wild-type; MRD, molecular residual disease.
